Therapeutic effects of telmisartan and irbesartan on hypertensive patients with overt diabetic nephropathy
Phase 4
- Conditions
- Hypertension, type 2 diabetes, diabetic nephropathy
- Registration Number
- JPRN-UMIN000001470
- Lead Sponsor
- Department of Cardiorenal Medicine, Yokohama City University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnant women, or women suspected of being pregnant 2. Hyperkalemia 3. History of hypersensitivity to Telmisartan or Irbesartan 4. Severe liver disorder, or severe biliary atresia. 5. Severe hypertension (clinic BP more than 180/100 mmHg).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Clinic blood pressure. 2. Ambulatory blood pressure monitoring: mean blood pressure, day-night variation, short-term blood pressure/heart rate variability, LF/HF. 3. Renal function: eGFR, urinary protein/albuminon excretion, urinary urea nitrogen, urinary type 4 collagen. 4. Glucose metabolism: fasting blood glucose, fasting IRI, HOMA-IR. 5. Lipid metabolism: total cholesterol, LDL, HDL, TG. 6. Renin-angiotensin system, inflammatory and oxidative stress markers: PRA, Urinary angiotensinigen, HMW-adiponectin, AGE, MDA-LDA, ADMA, cathecholamine. 7. Vascular function: ABI/baPWV.
- Secondary Outcome Measures
Name Time Method